Contineum Therapeutics, Inc. Insider Trading

CTNM

Last 12 months

Insiders sold $1.86M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. No executive or director has bought shares on the open market in the last two years.

Net open-market

−$1.86M

0 buys · 22 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

None

in the last two years

Get an email when CTNM's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 8	Carmine N. Stengone CEO and President	Sold10b5-1 plan	2,500	$16.46	41K	13%	Form 4
Aug 3	Carmine N. Stengone CEO and President	Sold10b5-1 plan	2,500	$16.01	40K	13%	Form 4
Jul 8 – 9	Daniel S. Lorrain Chief Scientific Officer	Sold10b5-1 plan 2 parts	1,040	$16.00 average	17K	0.7%	Form 4
Jul 8	Carmine N. Stengone CEO and President	Sold10b5-1 plan	2,500	$16.00	40K	13%	Form 4
Jun 30 – Jul 1	Daniel S. Lorrain Chief Scientific Officer	Sold10b5-1 plan 3 parts	37,179	$16.00 average	595K	20%	Form 4
Jun 30	Tim Watkins CMO & Head of Development	Sold10b5-1 plan	10,833	$16.02	174K	55%	Form 4
Jun 30	Carmine N. Stengone CEO and President	Sold10b5-1 plan	10,000	$16.01	160K	37%	Form 4
Jun 1	Daniel S. Lorrain Chief Scientific Officer	Sold10b5-1 plan	4,170	$13.16	55K	2.7%	Form 4
May 1	Daniel S. Lorrain Chief Scientific Officer	Sold10b5-1 plan 2 parts	4,170	$13.12 average	55K	2.7%	Form 4
Apr 6	Daniel S. Lorrain Chief Scientific Officer	Sold10b5-1 plan	4,170	$13.43	56K	2.6%	Form 4
Mar 2	Daniel S. Lorrain Chief Scientific Officer	Sold10b5-1 plan	4,170	$15.01	63K	2.6%	Form 4
Mar 2	Tim Watkins CMO & Head of Development	Sold10b5-1 plan	3,611	$15.02	54K	100%	Form 4
Feb 24 – 25	Carmine N. Stengone CEO and President	Sold10b5-1 plan 2 parts	7,100	$16.02 average	114K	32%	Form 4
Feb 24 – 25	Daniel S. Lorrain Chief Scientific Officer	Sold10b5-1 plan 2 parts	8,124	$16.02 average	130K	4.8%	Form 4
Feb 19	Daniel S. Lorrain Chief Scientific Officer	Sold10b5-1 plan	100	$16.00	2K	<0.1%	Form 4
Feb 11	Carmine N. Stengone CEO and President	Sold10b5-1 plan	400	$16.00	6K	2.6%	Form 4
Feb 11	Daniel S. Lorrain Chief Scientific Officer	Sold10b5-1 plan	400	$16.00	6K	0.2%	Form 4
Feb 3	Daniel S. Lorrain Chief Scientific Officer	Sold10b5-1 plan 2 parts	4,170	$14.94 average	62K	2.5%	Form 4
Jan 28	Tim Watkins CMO & Head of Development	Sold10b5-1 plan 2 parts	3,611	$14.18 average	51K	100%	Form 4
Jan 5	Daniel S. Lorrain Chief Scientific Officer	Sold10b5-1 plan 2 parts	4,170	$10.44 average	44K	2.4%	Form 4
Dec 29, 2025	Tim Watkins CMO & Head of Development	Sold10b5-1 plan	3,611	$12.06	44K	100%	Form 4
Dec 23, 2025	Daniel S. Lorrain Chief Scientific Officer	Sold10b5-1 plan	4,170	$12.23	51K	2.4%	Form 4
Nov 25, 2024	Daniel S. Lorrain Chief Scientific Officer	Sold10b5-1 plan	1,010	$16.02	16K	0.6%	Form 4
Nov 18, 2024	Daniel S. Lorrain Chief Scientific Officer	Sold10b5-1 plan 2 parts	6,190	$16.38 average	101K	3.4%	Form 4

Sep 810b5-1 plan
Carmine N. Stengone
CEO and President · sold 2,500 at $16.46
41K
13% of stake
Aug 310b5-1 plan
Carmine N. Stengone
CEO and President · sold 2,500 at $16.01
40K
13% of stake
Jul 8 – 910b5-1 plan
Daniel S. Lorrain
Chief Scientific Officer · sold 1,040 at avg $16.00
17K
0.7% of stake
Jul 810b5-1 plan
Carmine N. Stengone
CEO and President · sold 2,500 at $16.00
40K
13% of stake
Jun 30 – Jul 110b5-1 plan
Daniel S. Lorrain
Chief Scientific Officer · sold 37,179 at avg $16.00
595K
20% of stake
Jun 3010b5-1 plan
Tim Watkins
CMO & Head of Development · sold 10,833 at $16.02
174K
55% of stake
Jun 3010b5-1 plan
Carmine N. Stengone
CEO and President · sold 10,000 at $16.01
160K
37% of stake
Jun 110b5-1 plan
Daniel S. Lorrain
Chief Scientific Officer · sold 4,170 at $13.16
55K
2.7% of stake
May 110b5-1 plan
Daniel S. Lorrain
Chief Scientific Officer · sold 4,170 at avg $13.12
55K
2.7% of stake
Apr 610b5-1 plan
Daniel S. Lorrain
Chief Scientific Officer · sold 4,170 at $13.43
56K
2.6% of stake
Mar 210b5-1 plan
Daniel S. Lorrain
Chief Scientific Officer · sold 4,170 at $15.01
63K
2.6% of stake
Mar 210b5-1 plan
Tim Watkins
CMO & Head of Development · sold 3,611 at $15.02
54K
100% of stake
Feb 24 – 2510b5-1 plan
Carmine N. Stengone
CEO and President · sold 7,100 at avg $16.02
114K
32% of stake
Feb 24 – 2510b5-1 plan
Daniel S. Lorrain
Chief Scientific Officer · sold 8,124 at avg $16.02
130K
4.8% of stake
Feb 1910b5-1 plan
Daniel S. Lorrain
Chief Scientific Officer · sold 100 at $16.00
2K
<0.1% of stake
Feb 1110b5-1 plan
Carmine N. Stengone
CEO and President · sold 400 at $16.00
6K
2.6% of stake
Feb 1110b5-1 plan
Daniel S. Lorrain
Chief Scientific Officer · sold 400 at $16.00
6K
0.2% of stake
Feb 310b5-1 plan
Daniel S. Lorrain
Chief Scientific Officer · sold 4,170 at avg $14.94
62K
2.5% of stake
Jan 2810b5-1 plan
Tim Watkins
CMO & Head of Development · sold 3,611 at avg $14.18
51K
100% of stake
Jan 510b5-1 plan
Daniel S. Lorrain
Chief Scientific Officer · sold 4,170 at avg $10.44
44K
2.4% of stake
Dec 29, 202510b5-1 plan
Tim Watkins
CMO & Head of Development · sold 3,611 at $12.06
44K
100% of stake
Dec 23, 202510b5-1 plan
Daniel S. Lorrain
Chief Scientific Officer · sold 4,170 at $12.23
51K
2.4% of stake
Nov 25, 202410b5-1 plan
Daniel S. Lorrain
Chief Scientific Officer · sold 1,010 at $16.02
16K
0.6% of stake
Nov 18, 202410b5-1 plan
Daniel S. Lorrain
Chief Scientific Officer · sold 6,190 at avg $16.38
101K
3.4% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CTNM, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with CTNM

CompareIntrinsic value

KALVKalVista Pharmaceuticals Inc.

No recent price25

XOMAXOMA Corporation

€0.05-3.60%64

OCULOcular Therapeutix Inc.

$7.14+4.69%10

CARMCarisma Therapeutics Inc.

$0.00+100.00%60

SPROSpero Therapeutics Inc.

$1.07+2.88%63

GOSSGossamer Bio Inc.

$9.40+1.29%10

SIGASiga Technologies Inc.

$3.15+1.29%20

QTTBQ32 Bio Inc.

$8.97+2.40%60

Held by ETFs

CTNM is in 10 US ETFs. The largest of them, with CTNM's weight in each:

Spot a number that looks wrong? Check it in CTNM's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CTNM

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.